The present study found that T2DM patients with MASLD and metabolic hyperferritinemia had higher markers of liver steatosis and fibrosis (with an almost four-fold higher risk of advanced fibrosis), worse long-term glycemic control, and higher insulin resistance. This evidence concerns the gene INS and fatty liver disease.